Alexander Tells FDA To Create ‘Red Team’ For Regulatory Streamlining
This article was originally published in The Tan Sheet
Executive Summary
HELP Committee Chairman Lamar Alexander wants FDA to suggest regs and other bureaucratic requirements that are hindering productivity as part of medical innovation effort.
You may also be interested in...
FDA Simplifies The Process For REMS Changes
Some typographical changes can be submitted and noted later, according to new draft guidance. Major changes still require pre-approval.
FDA’s Top Two Reform Priorities Aren’t Really Legislative Material
Senate eyes a biomedical reform process that is simultaneously narrower and slower than the House’s 21st Century Cures Initiative; FDA’s Hamburg asks for ability to shape sponsor’s trial designs earlier and more regulatory science funding.
‘Precision Medicine’ Gets R&D Funding Push In President’s Speech
President Obama highlights potential for personalized medicine in his State of the Union address and will seek a “major increase” in research and development funding.